#evidencesynthesis
November 20, 2026 at 1:04 PM
eDiHTA scoping review narrows digital health patient evidence to 9 topics, 28 outcome measures. https://www.mattheneus.com/editorial/pubmed-digital-health-patient-related-outcome-measures-edihta-scoping-review-2026-11-20 #HTA #EvidenceSynthesis
November 21, 2026 at 9:04 AM
G-BA final resolution: aficamten (Myqorzo) added benefit not proven vs mavacamten in obstructive HCM.

https://www.mattheneus.com/editorial/g-ba-aficamten-myqorzo-hocm-mavacamten-not-proven-final-resolution-2026-11-19

#HTA #RegulatoryAffairs #EvidenceSynthesis
November 21, 2026 at 10:04 AM
Counting hospitalisations while patients die? The estimand must pick: Ghosh-Lin or Mao-Lin, pre-specified.

https://www.mattheneus.com/editorial/recurrent-terminal-event-estimand-ghosh-lin-mao-lin-endpoint-pre-specification-2026-11-22

#HTA #EvidenceSynthesis
November 22, 2026 at 5:04 PM
Across 59,400 clinical prediction models, sample size was not the main source of uncertainty: model applicability was. https://www.mattheneus.com/editorial/clinical-prediction-model-individual-risk-model-applicability-uncertainty-2026-11-21 #HTA #RWE #EvidenceSynthesis
November 21, 2026 at 5:04 PM
New reporting standard for reviews of published economic evaluations — what it changes for review teams.

https://www.mattheneus.com/editorial/prisma-econeval-2026-statement-reporting-items-economic-evaluation-reviews-2026-11-11

#HTA #EvidenceSynthesis #HealthEconomics
November 21, 2026 at 7:04 AM
37 Phase II trials borrowed external data. Most never reported the tuning parameter that decided how much borrowing happened.

https://www.mattheneus.com/editorial/bayesian-robust-borrowing-phase-two-trials-tuning-parameter-reporting-2026-11-21

#HTA #EvidenceSynthesis
November 21, 2026 at 10:05 PM
France wants demonstrated clinical benefit, not cholesterol targets, in its new global cardiovascular risk recommendation. https://www.mattheneus.com/editorial/has-global-cardiovascular-risk-primary-care-recommendation-grade-direct-benefit-2026-11-19 #HTA #EvidenceSynthesis
November 20, 2026 at 5:04 PM
Broader vaccine value fails on the indicator, not the argument. Delphi ranks what HTA can score first. https://www.mattheneus.com/editorial/vaccine-value-framework-delphi-priority-elements-hta-integration-2026-11-12 #HTA #HealthEconomics #EvidenceSynthesis
November 20, 2026 at 10:04 PM
In a Mexican Delphi on high-cost medicines, the only two criteria that failed consensus were both about local fit.

https://www.mattheneus.com/editorial/mexico-high-cost-medicines-deliberative-criteria-delphi-local-applicability-2026-11-22

#HTA #HealthEconomics #EvidenceSynthesis
November 22, 2026 at 12:04 PM
The target trial emulation label did not prevent immortal time bias: time zero still has to align. https://www.mattheneus.com/editorial/target-trial-emulation-time-zero-alignment-immortal-time-glp1-cancer-2026-11-21 #HTA #RWE #EvidenceSynthesis
November 21, 2026 at 5:04 PM
G-BA: no comparator data submitted, so deucravacitinib's added benefit in psoriatic arthritis stays unproven. https://www.mattheneus.com/editorial/g-ba-deucravacitinib-psoriatic-arthritis-no-comparator-data-added-benefit-not-proven-2026-11-19 #HTA #EvidenceSynthesis #RegulatoryAffairs
November 21, 2026 at 4:04 PM
Covariate balance is not causal identification. Unanchored MAIC still needs overlap and exchangeability to support any claim.

https://www.mattheneus.com/editorial/unanchored-maic-causal-identification-overlap-exchangeability-commentary-2026-11-19

#HTA #MAIC #EvidenceSynthesis
November 20, 2026 at 4:04 PM
Living systematic reviews now get their own Cochrane Handbook chapter. https://www.mattheneus.com/editorial/cochrane-handbook-chapter-21-living-evidence-prospective-meta-analysis-2026-11-10 #HTA #EvidenceSynthesis #RegulatoryAffairs
November 19, 2026 at 8:04 AM
No head-to-head data: G-BA rules added benefit not proven for marstacimab in haemophilia B with FIX inhibitors. https://www.mattheneus.com/editorial/g-ba-hympavzi-factor-ix-inhibitor-prophylaxis-resolution-no-head-to-head-evidence-2026-11-19 #HTA #NMA #MAIC #EvidenceSynthesis
November 22, 2026 at 9:04 AM
Assume a large GFAP biomarker effect and you need 52 patients; assume a modest one and you need 1,100. The same MS trial, sized by assumption. https://www.mattheneus.com/editorial/gfap-biomarker-outcome-multiple-sclerosis-trial-sample-size-scenarios-2026-11-22 #HTA #EvidenceSynthesis
November 22, 2026 at 7:04 AM
Cochrane found no clear turmeric benefit in knee osteoarthritis - and screening, not the spice, limits the evidence. https://www.mattheneus.com/editorial/cochrane-turmeric-curcuma-longa-osteoarthritis-review-awaiting-classification-2026-11-19 #HTA #EvidenceSynthesis
November 19, 2026 at 12:04 PM
Twenty-six normative guidance documents on polygenic risk scores — none recommends routine clinical use. https://www.mattheneus.com/editorial/polygenic-risk-score-normative-guidance-clinical-utility-thresholds-2026-11-18 #HTA #EvidenceSynthesis
November 18, 2026 at 11:04 PM
Flip the task order and children's stated preferences move: best-worst scaling and a discrete choice experiment disagreed. https://www.mattheneus.com/editorial/paediatric-preference-elicitation-best-worst-scaling-discrete-choice-task-order-2026-11-19 #HTA #EvidenceSynthesis
November 19, 2026 at 1:04 PM
Bayesian NMA ranks complement inhibitors in C3 glomerulopathy, then limits how far that SUCRA ranking can be read. https://www.mattheneus.com/editorial/pubmed-complement-inhibitors-c3-glomerulopathy-bayesian-nma-sucra-2026-11-18 #HTA #NMA #EvidenceSynthesis
November 19, 2026 at 8:04 AM
Single-reviewer risk-of-bias assessment is routine in rapid reviews. Across three reviews, agreement never exceeded Kappa 0.35. https://www.mattheneus.com/editorial/single-reviewer-risk-of-bias-accuracy-threshold-rapid-review-2026-11-19 #HTA #EvidenceSynthesis
November 19, 2026 at 7:04 AM
EMA's Amlypave withdrawal record: a narrowed kappa subgroup could not carry the effectiveness claim. https://www.mattheneus.com/editorial/ema-amlypave-anselamimab-kappa-amyloidosis-application-withdrawal-subgroup-evidence-2026-11-17 #HTA #RegulatoryAffairs #EvidenceSynthesis
November 18, 2026 at 4:04 AM
Four of nine primary outcome measures were recommended against use in their current form — PROM validity evidence is thinner than protocols imply. https://www.mattheneus.com/editorial/proms-measurement-properties-cosmin-primary-outcome-validity-2026-11-18 #HTA #EvidenceSynthesis
November 18, 2026 at 7:04 PM
One Cochrane review, two GRADE verdicts: daily oral iron probably cuts iron-deficiency anaemia in kids; broader anaemia effect very uncertain.
https://www.mattheneus.com/editorial/cochrane-daily-oral-iron-paediatric-anaemia-grade-certainty-split-2026-11-17
#HTA #EvidenceSynthesis
November 18, 2026 at 9:04 PM
If you've read or conducted reviews across disciplines, what similarities and differences have you noticed?

What could different fields learn from each other?

#SystematicReviews #EvidenceSynthesis #MetaAnalysis #SysRev
November 17, 2026 at 10:08 AM